We used a murine osteoblast immortalisation protocol that takes primary long bone derived osteoblasts and upon engineered deletion of p53 (R26-CreERT2Tp53fl/fl derived cells) these cells immortalise and have been demonstrated to generate osteosarcoma when transplanted in vivo (63,84–86). Here, TP53 is linked to osteosarcoma.